Previous 10 | Next 10 |
Vertex Pharmaceuticals ( NASDAQ: VRTX ) and Verve Therapeutics ( NASDAQ: VERV ) will collaborate on developing a gene editing program for a liver disease . Under the four-year arrangement, Verve ( VERV ) will be responsible for discovery, research and certa...
Verve Therapeutics ( NASDAQ: VERV ) shares dropped 16% postmarket on Wednesday after the firm announced a $200M underwritten stock offering . All shares are being offered by VERV. VERV expects to grant underwriters a 30-day option to buy up to an additional 15% of the ...
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public o...
BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today announced an exclusive, four-year global research collaboration focused on discovering and developing an in vivo gene ...
Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...
The recent stock rally has made some crowded shorts more squeezable, according to S3 Partners' Ihor Dusaniswky. Dusaniswky created a ranking of the most crowded shorts based on factors like total short dollars at risk, short interest as a true percentage of a company's tradable floa...
The shares of the gene editing company Verve Therapeutics ( NASDAQ: VERV ) jumped ~20% in the morning hours Monday recording the biggest intraday gain since June 2021 to reach the highest level since early March. About 764.5K Verve ( VERV ) shares have changed hand...
Verve Therapeutics has started a trial using CRISPR base editing technology to modify the PCSK9 gene in people with a disease called heterozygous familial hypercholesterolemia (HeFH). Familial hypercholesterolemia, for its part, is pretty much what the name implies: an inherited genet...
Development-stage biotech Verve Therapeutics ( NASDAQ: VERV ) announced on Tuesday that the company dosed the first patient in an early-stage trial for its lead asset and the in vivo base editing candidate VERVE-101. The heart-1 clinical trial is designed to evaluate VERVE-1...
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Dr...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...